BPC-157 Nasal Spray
The synthetic 15-residue gastric peptide as a sterile solution in bacteriostatic water, in a metered spray bottle. Made from a peptide lot tested in the manufacturer’s own laboratory, with a certificate.
| Compound | BPC-157 Body Protection Compound-157; pentadecapeptide |
|---|---|
| CAS number | 137525-51-0 |
| Molecular formula | C62H98N16O22 |
| Theoretical mass | 1419.6 Da |
| Sequence / structure | H-GEPPPGKPADDAGLV-OH (15 residues; free N- and C-termini) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a metered nasal spray bottle |
| Storage, sealed | Store at 2–8 °C, protected from light; do not freeze |
| Format | Solution in a metered nasal spray bottle |
Sizes and lots
- 10 mg · 1 bottle — $118.99
- 10 mg · Kit of 10 — $1057.82
BPC-157 is a 15-residue synthetic peptide, GEPPPGKPADDAGLV, whose sequence was found in a protein from human gastric juice. In this listing it comes as a sterile solution in bacteriostatic water, packed in a metered nasal spray bottle with the amount and concentration printed on the label. The research on BPC-157 is mostly rat and cell work on gut and soft-tissue injury, and a separate literature asks whether molecules sprayed into the nose can reach the brain.
What is in the bottle
The bottle holds BPC-157 dissolved in bacteriostatic water, which contains 0.9% benzyl alcohol as an antimicrobial preservative. The safety data sheet records the peptide content as stated on the label and below 10% w/v. It is the same sequence, theoretical mass 1419.6 Da, as in the freeze-dried vials. BPC-157 itself is not classified as hazardous, while benzyl alcohol carries warnings for harm if swallowed or inhaled, serious eye irritation and allergic skin reactions.
Keep the bottle upright with its cap on, at 2 to 8 °C and away from light, and do not freeze it. General guidance on keeping peptides and their solutions is in peptide storage and stability.
What the research covers
Sikiric's group in Zagreb described BPC-157 as an anti-ulcer peptide that remains stable in human gastric juice, with effects on gut lesions in rats and on the nitric oxide, dopamine and serotonin systems1. In 2018 Seiwerth and colleagues, co-authors of that review, compared it with EGF, FGF and VEGF and argued that it was the only one of the four that worked consistently across their gut injury models, before turning to tendon, ligament, muscle and bone2. That literature is large, but it comes mainly from one group and mainly from rats, and none of it concerns the nose.
A spray raises a different question. Lisbeth Illum wrote in 2004 that the blood-brain barrier keeps most polar and large drugs out of the brain, and that the olfactory pathway had drawn interest as a way around it3. She cited many animal studies, mostly in rats, that showed transport from nose to brain, and human studies with cerebrospinal fluid sampling that, in her opinion, confirmed a direct pathway was likely3. Nothing cited here gave BPC-157 by the nasal route, so whether a 1419.6 Da peptide crosses the nasal lining, and where it goes if it does, has not been measured. The BPC-157 research guide summarises the wider literature.
Frequently asked questions
Is the spray the same BPC-157 as the vials?
Yes: the same 15-residue sequence with free ends and a theoretical mass of 1419.6 Da. The vials keep it dry and frozen until it is dissolved, whereas the spray is already a solution in bacteriostatic water and is kept refrigerated, never frozen.
How much BPC-157 does the bottle contain?
The amount and concentration are printed on the bottle label, and the safety data sheet records the content as below 10% w/v. For work that needs a concentration set in the lab, the 5 mg and 10 mg vials supply a known mass of dry peptide to dissolve.
Has BPC-157 been studied as a nasal spray?
Not in any paper cited here. The BPC-157 studies are rat and cell experiments that used other routes, and the nasal delivery review concerns drugs in general. There are no published results specific to this format to report.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. DOI · PubMed
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. DOI · PubMed
- Illum L. Is nose-to-brain transport of drugs in man a reality?. J Pharm Pharmacol. 2004;56(1):3-17. DOI · PubMed
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.